ArticleCNS neuroscience & therapeutics2026
Growth Differentiation Factor 11 Is a Circulating Regulator of Oligodendrocyte Differentiation and CNS Myelin Formation and Repair.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsRemyelination failure is a major contributor to progressive neurological disability in multiple sclerosis (MS). Although oligodendrocyte progenitor cells (OPCs) persist in demyelinated lesions, they often fail to differentiate into myelinating oligodendrocytes. This study aimed to determine whether growth differentiation factor 11 (GDF11), a circulating member of the TGF-β superfamily, regulates oligodendrocyte differentiation, CNS myelination, and remyelination.
methodsThe effects of GDF11 were examined using purified mouse OPC cultures, a neonatal developmental myelination model, and two demyelination models: cuprizone-induced demyelination and experimental autoimmune encephalomyelitis (EAE). OPC differentiation was assessed by immunocytochemistry and morphological analysis. In vivo myelination and remyelination were evaluated using histological, ultrastructural, and behavioral approaches following systemic GDF11 administration.
resultsGDF11 directly promoted OPC differentiation and maturation in vitro without affecting proliferation. Systemic GDF11 enhanced developmental myelination in neonatal mice, increasing myelin gene expression, myelinated axon density, and myelin thickness. Although GDF11 did not prevent active demyelination, it significantly accelerated remyelination and functional recovery following cuprizone withdrawal and in the EAE model, and this was accompanied by enhanced oligodendrocyte differentiation and reduced neuroinflammation.
conclusionThese findings identify GDF11 as a circulating regulator of oligodendrocyte maturation and CNS myelin formation and repair, highlighting its therapeutic potential for demyelinating diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.